The Retrospective Analysis of Factors Determining the Success of Single-Dose Methotrexate Treatment in Ectopic Pregnancy
Main Article Content
Abstract
Objective: We aimed to investigate treatment outcomes, treatment failure rates, factors causing failure, and complications of treatment in patients followed up with ectopic pregnancy and receiving methotrexate (MTX) treatment.
Materials and methods: All ectopic pregnancies in a tertiary perinatology center who had single dose MTX between January 2015 and January 2021 were retrospectively included in this study. The demographic data of the women (age, gravida, parity, abortus numbers) and delivery [normal and cesarean sectio (C/S)] types were analyzed. The size of the mass, β-hCG level, presence of intra-abdominal free fluid and USG findings were recorded. The effectiveness of the treatment and the need for surgical treatment after MTX treatment were also investigated.
Results: Overall, 93 ectopic pregnancies who had single dose MTX treatment were included in this study. The mean age was 30.4 years (SD ± 5.2). Previous ectopic pregnancy rate was 9.9% and 13.6% had free fluid in the abdomen. More than one third (35.8%) had undergone previous surgery and 8.6% had chronic disease. The median β-hCG level was 1763 mIU/ml (minimum 129 – maximum 67854, IQR 1010 - 2723 mIU/ml). The mean size of the mass was 9.3 mm (SD±6.1). A single dose of MTX treatment was found to be effective in 51.9%. β-hCG levels at the time of admission, mass size, patients age and pregnancy week were not effective on the success of single-dose MTX treatment.
Conclusion: Single dose MTX therapy is used effectively and safely in the first treatment of ectopic pregnancy.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Nguyen PK, Wallach EE. Contemporary Diagnosis and Management of Ectopic Pregnancy. Topics in Obstetrics & Gynecology 1997: 17: p. 1.
II. Anderson FW, Hogan JG, Ansbacher R. Sudden death: ectopic pregnancy mortality. Obstetrics & Gynecology 2004: 103: 1218-1223.
III. Dogan A, Gulhan I, Uyar I, et al. Methotrexate treatment in progressive tubal ectopic pregnancies and hCG-related clinicosurgical implications. Kaohsiung J Med Sci 2016; 32:317-322. doi: 10.1016/j.kjms.2016.05.004
IV. Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med 2009 23;361:379-387. doi: 10.1056/NEJMcp0810384
V. Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999:23;341(26):1974-1978. doi: 10.1056/NEJM199912233412604
VI. Lipscomb GH, Bran D, McCord ML, Portera JC, Ling FW. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 1998;178:1354-8. doi: 10.1016/s0002-9378(98)70343-6
VII. Lipscomb GH, Gomez IG, Givens VM, Meyer NL, Bran DF. Yolk sac on transvaginal ultrasound as a prognostic indicator in the treatment of ectopic pregnancy with single-dose methotrexate. Am J Obstet Gynecol 2009;200:338.e1-4. doi: 10.1016/j.ajog.2008.12.006
VIII. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol 2003; 101:778-784. doi: 10.1016/s0029-7844(02)03158-7
IX. Nybo AA, Wohlfahrt J, Christens P, Olsen J, Melbye M. Is maternal age an independent risk factor for fetal loss? West J Med 2000;173:331. doi: 10.1136/ewjm.173.5.331
X. Bouyer J, Coste J, Shojaei T, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol 2003;157:185-194. doi: 10.1093/aje/kwf190
XI. Gunay T, Yardimci OD, Hocaoglu M, Demircivi Bor E, Turgut A, Karateke Ates. Factors Affecting Success of Single-Dose Methotreaxhate Treatment in Ectopic Pregnancy. Kocaeli Med J 2019; 8; 1:189-194
XII. Pasic R, Wolfe WM. Laparoscopic diagnosis and treatment of interstitial ectopic pregnancy: a case report. Am J Obstet Gynecol 1990;163(2):587-588. doi: 10.1016/0002-9378(90)91203-o
XIII. Pal A, Gupta KB, Sarin R. A study of ectopic pregnancy and high risk factors in Himachal Pradesh. J Indian Med Assoc 1996;94(5):172-173
XIV. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991-1997. Obstet Gynecol 2003; 101:289-296. doi: 10.1016/s0029-7844(02)02587-5
XV. Celik E, Türkçüoğlu I, Karaer A, Kırıcı P, Eraslan S. Assessment of early decline in the percentage of β-hCG values between days 0 and 4 after methotrexate therapy in ectopic pregnancy for the prediction of treatment success. J Turk Ger Gynecol Assoc 2013; 14:125-129. doi: 10.5152/jtgga.2013.50133
XVI. Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87(3):481-484. doi: 10.1016/j.fertnstert.2006.10.007
XVII. Kirk E, Condous G, Van Calster B, et al. A validation of the most commonly used protocol to predict the success of single-dose methotrexate in the treatment of ectopic pregnancy. Hum Repro. 2007; 22:858-863. doi: 10.1093/humrep/del433
XVIII. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol 2003; 101:778-784. doi: 10.1016/s0029-7844(02)03158-7
XIX. Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol 1991; 77:754-757
XX. Stika CS, Anderson L, Frederiksen MC. Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. Am J Obstet Gynecol 1996; 174:1840-1846.
doi: 10.1016/s0002-9378(96)70219-3
XXI. Nazac A, Gervaise A, Bouyer J, de Tayrac R, Capella-Allouc S, Fernandez H. Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. Ultrasound Obstet Gynecol 2003: 21:181-5. doi: 10.1002/uog.9.
XXII. Nowak-Markwitz E, Michalak M, Olejnik M, Spaczynski M. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril 2009; 92:1203-1207. doi: 10.1016/j.fertnstert.2008.07.1775